SAN RAFAEL, Calif., Sept. 17, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced highlights to be presented at the company's Research and Development Day for the investment community to be held today from 8:00 a.m. to 12:00 p.m. ET. Members of BioMarin's management team and industry experts will provide an update on the company's product portfolio and advancements in the research and development pipeline. Interested parties may access a live audio webcast and slides of the presentation via the investor section of the BioMarin website, http://www.BMRN.com.
Vimizim for the Treatment of Morquio A
BioMarin announced today that it expects that Vimizim will be reviewed by the U.S. Food and Drug Administration Advisory Committee on November 19, 2013. The Company noted that the FDA has previously granted Vimizim priority review designation and assigned a PDUFA date of February 28, 2014. The European Medicines Agency (EMA) has validated the Vimizim Marketing Authorization Application (MAA) and has granted accelerated review status, which could lead to a (Committee for Medicinal Products for Human Use) CHMP opinion before year end. During the second quarter of 2013, the company also submitted the Marketing Authorisation (MA) in Brazil. Ongoing production of bulk drug substance and drug product will allow for a global launch of Vimizim following approvals in multiple countries. Both the FDA and EMA have conducted or scheduled pre-approval inspections associated with the review of the marketing applications.
BMN 701 for the Treatment of Pompe Disease
The company announced that it has received agreement from the FDA that Maximal Inspiratory Pressure (MIP) may be utilized as the primary endpoint for its anticipated Phase 3 switching trial with BMN-701, a fusion protein of insulin-like growth factor 2 and acid alphaglucosidase (IGF2-GAA) for the treatment of late-onset Pompe disease. Discussions with European regulators regarding primary endpoint and study design are still ongoing.
Subject to completing discussions with European health authorities, the company expects to initiate a Phase 3 switching trial by the fourth quarter of 2013 or the first quarter of 2014 in late-onset Pompe patients who have previously been treated with alglucosidase alfa. The proposed study design is a single-arm trial, with treatment at 20 mg/kg administered every other week for 24 weeks. The company intends to use efficacy as measured by the respiratory parameter MIP as the primary endpoint. MIP is the maximal pressure that can be produced by the patient trying to inhale through a blocked mouthpiece. Secondary objectives include MEP and six-minute walk test, as well as safety. The study will be conducted with full scale material from a revised manufacturing process, which has improved process robustness and increased productivity.
BMN 111 for the Treatment of Achondroplasia
The company announced today that based on recent meetings with the FDA and the Medicines and Healthcare Products Regulatory Agency (MHRA) it will be able to proceed directly to a Phase 2 study of BMN 111, an analog of C-type Natriuretic Peptide (CNP), for achondroplasia. BioMarin previously completed a Phase 1 study in adult healthy volunteers. The FDA had placed a partial clinical hold on BMN 111, but at a recent meeting indicated that following submission of a modified Phase 2 protocol, and withdrawal of the previous Phase 2 study protocol, the clinical hold can be lifted and that no further data is required before initiating a Phase 2 study. The company expects to initiate its first global study in pediatric patients with achondroplasia in the fourth quarter of 2013 or the first quarter of 2014.
BMN 190 for the Treatment of Batten Disease
The company announced today that it has initiated the Phase 1/2 study for BMN 190, a recombinant human tripeptidyl peptidase 1 (rhTPP1) for the treatment of patients with neuronal ceroid lipofuscinosis type 2 (NCL-2), a form of Batten disease. The first patient has been enrolled and is expected to receive initial drug dosing within 7 days.
The Phase 1/2 study is an open-label, dose-escalation study in patients with NCL-2. The primary objectives are to evaluate the safety and tolerability of BMN 190 and to evaluate effectiveness using an NCL-2-specific rating scale score in comparison with natural history data after 48 weeks of treatment. Secondary objectives are to evaluate the impact of treatment on brain atrophy in comparison with NCL-2 natural history after 48 weeks of treatment and to characterize pharmacokinetics and immunogenicity. The study will enroll approximately 22 subjects at up to ten clinical sites worldwide for a treatment duration of 48 weeks.
BMN 673 for the Treatment of gBRCA Breast Cancer
With BMN 673 PARP inhibition with BMN 673 in ovarian and breast cancer patients with deleterious mutations of BRCA1 and BRCA2 has been selected as a late breaking abstract by the 17th ECCO — 38th ESMO — 32nd ESTRO European Cancer Congress in Amsterdam, The Netherlands and will be presented in an oral presentation on September 29, 2013.
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include BMN 110 (N-acetylgalactosamine 6-sulfatase), formally referred to as GALNS, which successfully completed Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase III clinical development for the treatment of PKU, BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase III clinical development for the treatment of genetically-defined cancers, BMN 111, a modified C-natriuretic peptide, which is currently in Phase I clinical development for the treatment of achondroplasia, and BMN 190, a recombinant human tripeptidyl peptidase 1 (rhTPP1), which is currently in Phase 1/2 development for the treatment of neuronal ceroid lipofuscinosis Type 2 disease. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.
This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about our expectations regarding the design, progress and timing of BioMarin's clinical trials of BMN-673, BMN-701, BMN-111 and BMN-190; our expectations regarding the timing of the FDA Advisory Committee Meeting and CHMP opinion for Vimizim; our expectations regarding the timing of our regulatory filings for Vimizim, BMN-673, BMN-701, BMN-111 and BMN-190; actions by regulatory authorities, particularly actions related to the approval of Vimizim. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the continued commercialization of Naglazyme, Kuvan, and Firdapse; Genzyme Corporation's success in continuing the commercialization of Aldurazyme; results and timing of current and planned preclinical studies and clinical trials, particularly with respect to BMN-673, BMN-701, BMN 190 and BMN-111; our ability to successfully manufacture our products and product candidates and to pass pre-approval inspections with the FDA and EMA related to the approval of Vimizim; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning Vimizim and each of the other described products and product candidates; and those risks that are discussed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, BioMarin's 2012 Annual Report on Form 10-K, and our periodic reports on Form 10-Q and Form 8-K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.
BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.
Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.
CONTACT: Investors: Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media: Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451